蒙药桑塔乐-25治疗重症肺炎的临床疗效OA

Objective To investigate the clinical efficacy and safety of the Mongolian medicine Sangtale-25 in the treatment of severe bacterial pneumonia.Methods A total of 90 patients with severe bacterial pneumonia who were hospitalized in the emergency and critical care center,department of respiratory medicine,and department of pulmonary diseases of International Mongolian Hospital of Inner Mongolia Autonomous Region from April 2023 to April 2025 were enrolled as research subjects.The patients were randomly assigned to a control group and a experimental group using a random number table,with 45 patients in each.The control group received conventional Western medical treatment combined with intravenous injection of cefoperazone sodium/sulbactam sodium and ambroxol hydrochloride.On this basis,the treatment group additionally received Sangtale-25.Both groups were treated for 2 weeks.The differences in inflammatory markers,including C-reactive protein(CRP),procalcitonin(PCT),interleukin-6(IL-6),and white blood cell count(WBC),Mongolian medicine syndrome scores,pulmonary function parameters[forced expiratory volume in one second(FEV1)and forced vital capacity(FVC)],clinical pulmonary infection score(CPIS),acute physiology and chronic health evaluation Ⅱ(APACHEⅡ)score,duration of mechanical ventilation,length of intensive care unit(ICU)stay,clinical efficacy,and incidence of adverse reactions were compared between the two groups after treatment.Results After treatment,inflammatory markers(CRP,PCT,WBC,and IL-6),pulmonary function parameters(FEV1 and FEV1/FVC),Mongolian medicine syndrome scores,CPIS,and APACHEⅡscores were significantly improved in both groups compared with those before treatment[control group:CRP(mg/L)was 34.39±6.09 vs.84.35±24.64,PCT(mg/L)was 2.08±0.60 vs.4.97±0.55,WBC(×109/L)was 8.84±1.15 vs.12.97±1.06,IL-6(ng/L)was 0.96±0.54 vs.5.55±0.85,FEV1(L)was 1.60±0.43 vs.1.12±0.37,FEV1/FVC was(69.34±2.36)%vs.(50.00±3.19)%,cough/sputum score was 5.48±1.21 vs.9.60±1.67,fever/irritation score was 4.55±1.45 vs.8.40±1.61,CPIS score was 5.06±1.28 vs.9.13±1.30,APACHEⅡ score was 9.33±1.52 vs.24.22±2.68;experimental group:CRP(mg/L)was 23.39±4.98 vs.85.50±26.86,PCT(mg/L)was 1.60±0.76 vs.4.90±0.59,WBC(×109/L)was 7.88±1.34 vs.12.93±1.19,IL-6(ng/L)was 0.61±0.37 vs.5.58±0.84,FEV1(L)was 2.00±0.56 vs.1.07±0.47,FEV1/FVC was(76.96±4.73)%vs.(50.37±2.75)%,cough/sputum score was 3.95±1.38 vs.9.62±1.77,fever/irritation score was 3.53±1.34 vs.8.33±1.67,CPIS score was 4.04±1.34 vs.9.02±1.32,APACHEⅡ score was 6.40±1.97 vs.23.42±2.45;all P<0.05],and the improvement degree of the experimental group was more significant than that of the control group[CRP(mg/L):23.39±4.98 vs.34.39±6.09,PCT(mg/L):1.60±0.76 vs.2.08±0.60,WBC(×109/L):7.88±1.34 vs.8.84±1.15,IL-6(ng/L):0.61±0.37 vs.0.96±0.54,FEV1(L):2.00±0.56 vs.1.60±0.43,FEV1/FVC:(76.96±4.73)%vs.(69.34±2.36)%;cough/sputum score:3.95±1.38 vs.5.48±1.21;fever/irritation score:3.53±1.34 vs.4.55±1.45;CPIS:4.04±1.34 vs.5.06±1.28;APACHEⅡ score:6.40±1.97 vs.9.33±1.52;all P<0.05].The duration of mechanical ventilation and length of ICU stay were significantly shorter in the treatment group than those in the control group[duration of mechanical ventilation(days):3.15±1.08 vs.3.97±1.54,ICU stay(days):8.75±2.10 vs.9.93±2.29;both P<0.05].The overall response rate was significantly higher in the treatment group than in the control group[93.33%(42/45)vs.82.22%(37/45),P<0.05].There was no statistically significant difference in the incidence of adverse reactions between the two groups.Conclusions Mongolian medicine Santale-25 in the treatment of severe pneumonia can reduce inflammatory markers and Mongolian medicine syndrome manifestations in patients,improve pulmonary function,alleviate clinical symptoms,and shorten the duration of mechanical ventilation and ICU stay,thereby improving overall clinical efficacy.